SG10201900212QA - Checkpoint kinase 1 inhibitors for potentiating dna damaging agents - Google Patents
Checkpoint kinase 1 inhibitors for potentiating dna damaging agentsInfo
- Publication number
- SG10201900212QA SG10201900212QA SG10201900212QA SG10201900212QA SG10201900212QA SG 10201900212Q A SG10201900212Q A SG 10201900212QA SG 10201900212Q A SG10201900212Q A SG 10201900212QA SG 10201900212Q A SG10201900212Q A SG 10201900212QA SG 10201900212Q A SG10201900212Q A SG 10201900212QA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- dna damaging
- damaging agents
- checkpoint kinase
- potentiating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16856309P | 2009-04-11 | 2009-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201900212QA true SG10201900212QA (en) | 2019-02-27 |
Family
ID=42651200
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201900212QA SG10201900212QA (en) | 2009-04-11 | 2010-04-09 | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents |
| SG10201404012RA SG10201404012RA (en) | 2009-04-11 | 2010-04-09 | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents |
| SG2011075520A SG175242A1 (en) | 2009-04-11 | 2010-04-09 | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201404012RA SG10201404012RA (en) | 2009-04-11 | 2010-04-09 | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents |
| SG2011075520A SG175242A1 (en) | 2009-04-11 | 2010-04-09 | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents |
Country Status (15)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2242755B1 (en) | 2008-01-08 | 2012-09-12 | Array Biopharma, Inc. | Pyrrolopyridines as kinase inhibitors |
| US8372842B2 (en) | 2008-01-09 | 2013-02-12 | Array Biopharma Inc. | Pyrazolopyridines as kinase inhibitors |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CA2817968C (en) * | 2010-11-16 | 2019-03-12 | Array Biopharma Inc. | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
| GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2015053402A1 (ja) | 2013-10-11 | 2015-04-16 | 国立大学法人東京医科歯科大学 | 脊髄小脳変性症を予防又は治療するための薬剤 |
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| WO2020150417A2 (en) * | 2019-01-17 | 2020-07-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| KR102285996B1 (ko) * | 2019-08-08 | 2021-08-05 | 차의과학대학교 산학협력단 | 혈관신생을 억제하는 데 사용하기 위한 조성물 및 그 용도 |
| WO2021113661A1 (en) | 2019-12-05 | 2021-06-10 | Seagen Inc. | Amorphous and polymorphic form of a specific chk1 inhibitor |
| GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003028724A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| MXPA06003110A (es) * | 2003-09-17 | 2006-06-20 | Icos Corp | Uso de inhibidores de chk1 para controlar la proliferacion celular. |
| UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| BRPI0709731A2 (pt) * | 2006-04-04 | 2011-07-26 | Pfizer Prod Inc | terapia de combinaÇço de (2r,z)-2-amino-2-cicloexil-n-(5-(1-metil-1h-pirazol-4-il)-1- oxo-2,6-diidro-1h-[1,2]diazepino[4,5,6-cd]indol-8-il)acet amida |
| EP2086644A2 (en) * | 2006-11-17 | 2009-08-12 | Schering Corporation | Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders |
| AR071717A1 (es) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
-
2010
- 2010-04-09 JP JP2012504909A patent/JP5805071B2/ja not_active Expired - Fee Related
- 2010-04-09 WO PCT/US2010/030634 patent/WO2010118390A1/en active Application Filing
- 2010-04-09 RU RU2011145773/15A patent/RU2567044C2/ru active
- 2010-04-09 CN CN201080025806.6A patent/CN102612365B/zh not_active Expired - Fee Related
- 2010-04-09 SG SG10201900212QA patent/SG10201900212QA/en unknown
- 2010-04-09 BR BRPI1013920A patent/BRPI1013920A2/pt not_active Application Discontinuation
- 2010-04-09 SG SG10201404012RA patent/SG10201404012RA/en unknown
- 2010-04-09 CA CA2758300A patent/CA2758300C/en active Active
- 2010-04-09 KR KR1020117026769A patent/KR101676062B1/ko not_active Expired - Fee Related
- 2010-04-09 EP EP10721579.0A patent/EP2416773B1/en active Active
- 2010-04-09 NZ NZ596125A patent/NZ596125A/xx not_active IP Right Cessation
- 2010-04-09 ES ES10721579.0T patent/ES2608656T3/es active Active
- 2010-04-09 MX MX2011010675A patent/MX341368B/es active IP Right Grant
- 2010-04-09 AU AU2010233122A patent/AU2010233122B2/en not_active Ceased
- 2010-04-09 SG SG2011075520A patent/SG175242A1/en unknown
-
2011
- 2011-10-11 IL IL215709A patent/IL215709A/en active IP Right Grant
- 2011-11-10 ZA ZA2011/08273A patent/ZA201108273B/en unknown
-
2014
- 2014-07-29 JP JP2014153687A patent/JP2014198741A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010233122A1 (en) | 2011-11-24 |
| EP2416773B1 (en) | 2016-09-28 |
| CA2758300C (en) | 2017-07-25 |
| CA2758300A1 (en) | 2010-10-14 |
| RU2567044C2 (ru) | 2015-10-27 |
| MX2011010675A (es) | 2012-03-16 |
| SG10201404012RA (en) | 2014-09-26 |
| MX341368B (es) | 2016-08-17 |
| JP2012523435A (ja) | 2012-10-04 |
| IL215709A (en) | 2017-06-29 |
| SG175242A1 (en) | 2011-11-28 |
| BRPI1013920A2 (pt) | 2016-04-05 |
| JP2014198741A (ja) | 2014-10-23 |
| ES2608656T3 (es) | 2017-04-12 |
| AU2010233122B2 (en) | 2015-09-17 |
| WO2010118390A1 (en) | 2010-10-14 |
| KR20120004523A (ko) | 2012-01-12 |
| JP5805071B2 (ja) | 2015-11-04 |
| KR101676062B1 (ko) | 2016-11-14 |
| IL215709A0 (en) | 2012-01-31 |
| ZA201108273B (en) | 2013-07-31 |
| CN102612365A (zh) | 2012-07-25 |
| CN102612365B (zh) | 2017-04-12 |
| RU2011145773A (ru) | 2013-05-20 |
| NZ596125A (en) | 2012-08-31 |
| EP2416773A1 (en) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201900212QA (en) | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents | |
| MX359406B (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3kpara usarse en el tratamiento de cáncer. | |
| TN2009000400A1 (en) | Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha | |
| UA115320C2 (uk) | Інгібітори кінази | |
| EP1962839A4 (en) | ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER | |
| UA106748C2 (uk) | Похідні проліну як інгібітори катепсину | |
| ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
| JO3073B1 (ar) | مثبطات ثنائية ملتحمة ثلاثية الحلقة ل cdk 4/6 و flt3 | |
| UA98141C2 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
| EA201070237A1 (ru) | Четвертичные опиоидные карбоксамиды | |
| UY33498A (es) | Combinaciones de inhibidores de quinasas para el tratamiento de cancer | |
| MY150547A (en) | Protein kinase inhibitors | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| MX343669B (es) | Combinacion de inhibidores de la cinasa de control 1 inhibidores de la cinasa wee 1. | |
| GEP20166455B (en) | Methods of administering pirfenidone therapy | |
| PH12012502129A1 (en) | New combination therapy in treatment of oncological and fibrotic diseases | |
| BR112012026338A2 (pt) | novos derivados de 3,3-dimetil tetrahidroquinolina | |
| MX2011011733A (es) | Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. | |
| WO2009127669A3 (en) | Ido inhibitors and therapeutic uses thereof | |
| NZ594365A (en) | Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders | |
| IN2012DN00765A (enrdf_load_stackoverflow) | ||
| HUE039768T2 (hu) | Terápiás szer anaerob betegségekre | |
| IN2012DN01273A (enrdf_load_stackoverflow) | ||
| SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| MX2015012386A (es) | Inhibidores de la cinasa cdk9. |